Key Points

  • Nuwellis Inc. (NASDAQ: NUWE) has a beta of 0.28.
  • The company’s per share price is $8.90, with a market valuation of $4.98M.
  • Analysts have given the stock a consensus recommendation of a Buy.
  • The company’s EPS for the current quarter is expected to be -$0.32.
  • Data shows Nuwellis Inc.'s share value has grown at a faster rate than its peers in the industry.

The healthcare sector has seen significant advancements in recent years, with new treatments and technologies emerging on a regular basis.

With the growth of the industry, the number of players in the market has also increased, and Nuwellis Inc. (NASDAQ: NUWE) is one of the companies that has come into prominence in recent times. In this article, we'll take a closer look at the company, its performance, and the potential it has to offer as a good investment opportunity.

Image Description

Company Overview

Nuwellis Inc. is a pharmaceutical company that focuses on developing and commercializing innovative treatments for unmet medical needs. The company's pipeline includes drugs that are in different stages of development, including preclinical, clinical, and post-approval stages. The company has a strong research and development team, which is continuously working to develop new treatments to meet the needs of patients worldwide.

In the last trading session, 3.09 million Nuwellis Inc. shares changed hands as the company’s beta touched 0.28. The company's per share price was $8.90, and it traded at $1.23 or 16.04% during the last session. The market valuation stood at $4.98 million. The company's last price was considered a discount, traded about -1978.65% off its 52-week high of $185.00. The share price had its 52-week low at $6.08, which suggests the last value was 31.69% up since then.

The company's average trading volume for the 10-day period is 0.35 million shares, and the 3-month average is 380.78K. When it comes to analyst recommendations, the consensus is a Buy, with a mean rating of 1.70. Out of the 3 analysts that rate the stock, none have rated it as a Sell, and none have given it an Overweight rating. Of the remaining, 0 have recommended NUWE as a Hold, 3 have rated it as a Buy, and 0 have rated it as Underweight. The company's expected EPS for the current quarter is -$0.32.

Image Description

Nuwellis Inc. has been performing relatively well compared to most of its peers in the industry. The company's share value has shot -84.18% over the past 6 months, a 99.31% annual growth rate that is considerably higher than the industry average of 1.50%.

Analysts have upgraded their fiscal year 2023 revenue estimates, predicting that the current quarter's revenue for Nuwellis Inc. will rise 57.30%. The growth in revenue is estimated to hit 19.50% for the next quarter, and year-over-year growth is forecast to reach 11.90% up from the last financial year.

Potential for Growth and Investor Considerations

Nuwellis Inc. is a young and growing company that has a strong focus on research and development. The company's pipeline includes drugs that are in different stages of development, and it has a strong team working to develop new treatments. As the healthcare sector continues to grow and evolve, there is a lot of potential for companies like Nuwellis Inc. to grow and succeed.

When investing in Nuwellis Inc., it's important to keep in mind that the company is a young and growing company that is still in the early stages of development. This means that there is a lot of potential for growth, but also some risk involved. Investors should consider the company's performance, analyst recommendations, and their own financial goals and risk tolerance before making



About Nuwellis, Inc.


  • Ticker NUWE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 31,531,600
  • Market Cap $8.2M
  • Description
  • Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex ...
More about NUWE